The latest price target for PaxMedica (OTCPK:PXMD) was reported by HC Wainwright & Co. on December 4, 2023. The analyst firm set a price target for $3.00 expecting PXMD to rise to within 12 months (a possible 971.43% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for PaxMedica (OTCPK:PXMD) was provided by HC Wainwright & Co., and PaxMedica initiated their buy rating.

There is no last upgrade for PaxMedica

There is no last downgrade for PaxMedica.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PaxMedica, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PaxMedica was filed on December 4, 2023 so you should expect the next rating to be made available sometime around December 4, 2024.

While ratings are subjective and will change, the latest PaxMedica (PXMD) rating was a initiated with a price target of $0.00 to $3.00. The current price PaxMedica (PXMD) is trading at is $0.28, which is within the analyst’s predicted range.